Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Nicolini FE, Etienne G, Huguet F, Charbonnier A, Roth-Guépin G, Escoffre-Barbe M, Dubruille V, Johnson-Ansah H, Rousselot P, Legros L, Parry A, Roy L, Coiteux V, Lenain P, Ianotto JC, Doublet C, Orvain C, Simonet-Boissard M, Chrétien ML, Penot A, Meunier M, Amé S, Hermet E, Quittet P, Lapusan S, Schwiertz V, Cayuela JM, Mauté C, Réa D, Morisset S, Mahon FX, Dulucq S

Open source

DOI: 10.1016/s2352-3026(26)00043-8
Published: 2026 May
Container: The Lancet. Haematology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00043-8,
  title = {Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.},
  author = {Nicolini FE and Etienne G and Huguet F and Charbonnier A and Roth-Guépin G and Escoffre-Barbe M and Dubruille V and Johnson-Ansah H and Rousselot P and Legros L and Parry A and Roy L and Coiteux V and Lenain P and Ianotto JC and Doublet C and Orvain C and Simonet-Boissard M and Chrétien ML and Penot A and Meunier M and Amé S and Hermet E and Quittet P and Lapusan S and Schwiertz V and Cayuela JM and Mauté C and Réa D and Morisset S and Mahon FX and Dulucq S},
  year = {2026},
  journal = {The Lancet. Haematology},
  doi = {10.1016/s2352-3026(26)00043-8},
  url = {https://doi.org/10.1016/s2352-3026(26)00043-8}
}

RIS

TY  - JOUR
TI  - Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.
AU  - Nicolini FE
AU  - Etienne G
AU  - Huguet F
AU  - Charbonnier A
AU  - Roth-Guépin G
AU  - Escoffre-Barbe M
AU  - Dubruille V
AU  - Johnson-Ansah H
AU  - Rousselot P
AU  - Legros L
AU  - Parry A
AU  - Roy L
AU  - Coiteux V
AU  - Lenain P
AU  - Ianotto JC
AU  - Doublet C
AU  - Orvain C
AU  - Simonet-Boissard M
AU  - Chrétien ML
AU  - Penot A
AU  - Meunier M
AU  - Amé S
AU  - Hermet E
AU  - Quittet P
AU  - Lapusan S
AU  - Schwiertz V
AU  - Cayuela JM
AU  - Mauté C
AU  - Réa D
AU  - Morisset S
AU  - Mahon FX
AU  - Dulucq S
PY  - 2026
JO  - The Lancet. Haematology
DO  - 10.1016/s2352-3026(26)00043-8
UR  - https://doi.org/10.1016/s2352-3026(26)00043-8
ER  -

APA

FE, N., G, E., F, H., A, C., G, R., M, E., V, D., H, J., P, R., L, L., A, P., L, R., V, C., P, L., JC, I., C, D., C, O., M, S., ML, C., A, P., M, M., S, A., E, H., P, Q., S, L., V, S., JM, C., C, M., D, R., S, M., FX, M., & S, D. (2026). Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(26)00043-8

Source records

pubmed · retrieved 2026-09-27T01:36:58.203Z
europe-pmc · retrieved 2026-09-27T01:36:58.207Z